Phase III trials of the vaccine produced by the Indian company Bharat Biotech have shown it to be 93.4% effective against severe symptomatic COVID-19.
In addition, the data showed that the vaccine provides 65.2% protection against the Delta strain.
A self-produced vaccine in India was also shown to be 77.8% effective against symptomatic COVID-19 in a trial.
The Covaxin vaccine was produced in India by Bharat Biotech Supported by the Government of India. At first, it was expected that the vaccine would not be exported to other countries, it was created for domestic use in the country.
Now that a severe pandemic has been overcome, the company is talking about increasing production Covaxin. Bharat Biotech estimates that 23 million doses will be produced per month.
Also Ocugen, which is working with Bharat Biotech to develop Covaxin for the US market, is preparing to request full US approval of its vaccine.
– .
